This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
The EFF is a growing multiple stakeholder platform for the exchange and sharing of insights and innovations to drive the future of clinical development in inherited retinal diseases. Organized by ProQR
… Unlocking the Potential of Innovative Editing Oligonucleotides to Address Liver … Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive … and development and is currently in charge of our Innovation unit. Axiomer ® , an RNA editing platform, uses …
ProQR recognizes the importance of advancing diversity, equity, and inclusivity (DEI) in the workplace to inspire each employee to fully thrive and to make their maximum contribution to ProQR.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … applied clinical quantitative sciences and a passion for innovation in drug development. Location: Leiden, NL Key …
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … integration and alignment of research efforts, driving innovation and efficiency in drug development. Proactively …
